RADIANCE II ピボタル研究: ステージ II 高血圧症における ReCor Medical Paradise システムの研究 (RADIANCE-II)
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Galway、アイルランド、H91 YR71
- University Hospital Galway
-
-
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35211
- Cardiology PC
-
-
California
-
Los Angeles、California、アメリカ、940048
- Cedars Sinai Medical Center
-
-
Connecticut
-
Bridgeport、Connecticut、アメリカ、06610
- Bridgeport Hospital
-
Stamford、Connecticut、アメリカ、06904
- Stamford Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- MedStar Washington
-
-
Florida
-
Gainsville、Florida、アメリカ、32605
- The Cardiac and Vascular Institute
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- Emory University Hospital Midtown
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Springfield、Illinois、アメリカ、62794
- Southern Illinois University
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Heart and Vascular Institute
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02120
- The Brigham and Women's Hospital
-
-
Michigan
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Health System
-
-
Nevada
-
Reno、Nevada、アメリカ、89502
- Renown Regional Medical Center
-
-
New Jersey
-
Browns Mills、New Jersey、アメリカ、08015
- Deborah Heart & Lung Center
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University
-
-
New York
-
New York、New York、アメリカ、10032
- Columbia University Medical Center/NYPH
-
New York、New York、アメリカ、10075
- Northwell Health Inc.
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- The University of North Carolina at Chapel Hill
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania Health System
-
Pittsburgh、Pennsylvania、アメリカ、15213
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38163
- The University of Tennessee Health Science Center
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84132
- University of Utah
-
-
Washington
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center
-
-
-
-
-
Bournemouth、イギリス、BH7 7DW
- University Hospitals Dorset NHS Foundation Trust
-
Canterbury、イギリス、CT1 3NG
- Kent & Canterbury Hospital
-
Cardiff、イギリス
- University Hospital Wales
-
London、イギリス、EC1A 7BE
- St Bartholomew's Hospital
-
Newcastle upon Tyne、イギリス、NE7 7DN
- Freeman Hospital
-
-
Essex
-
Basildon、Essex、イギリス、SS16 5NL
- The Cardiothoracic Centre Basildon University Hospital
-
-
-
-
-
Rotterdam、オランダ、3015 GD
- Erasmus Medical Center
-
-
-
-
-
Geneva、スイス、1211
- Hôpitaux Universitaires Genève
-
-
-
-
-
Erlangen、ドイツ、D-91054
- University Clinic Erlangen
-
Homburg、ドイツ、D-66421
- University Clinic of Saarland - Homburg
-
Karlsruhe、ドイツ、76133
- Klinikum Karlsruhe GmbH
-
Konstanz、ドイツ、D-78464
- Klinikum Konstanz
-
Leipzig、ドイツ、D-04289
- Herzzentrum Leipzig GmbH
-
Lübeck、ドイツ、D-23560
- Sana Kliniken Lübeck GmbH
-
-
-
-
-
Bordeaux、フランス、33000
- Hôpital Saint André
-
Lille、フランス、59000
- CHRU de Lille
-
Paris、フランス、75015
- Hôpital Européen Georges-Pompidou (HEGP)
-
-
-
-
-
Brussels、ベルギー、1000
- Centre Hospitalier Universitaire Saint-Pierre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Previously or currently prescribed antihypertensive therapy
- Average office BP ≥ 140/90 mmHg <180/120 mmHg while stable for at least 4 weeks on 0-2 classes of antihypertensive medication
- Documented daytime ABP ≥ 135/85 mmHg and < 170/105 mmHg after 4-week washout/run-in period
Exclusion Criteria:
- Lacks appropriate renal artery anatomy for treatment
- Known, uncorrected causes of secondary hypertension other than sleep apnea
- Type I diabetes mellitus or uncontrolled Type II diabetes
- eGFR of <40
- Brachial circumference ≥ 42 cm
- Any history of cerebrovascular event or severe cardiovascular event, or history of stable or unstable angina within 12 months prior to consent
- Repeat (>1) hospitalization for hypertensive crisis within 12 months prior to screening period, or any hospitalization for hypertensive crisis within 3 months prior to screening period
- Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
- Primary pulmonary hypertension
- Night shift workers
- Pregnant, nursing or planning to become pregnant
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Renal Denervation
Renal Angiogram and Renal Denervation (Paradise Renal Denervation System) |
Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
他の名前:
|
|
偽コンパレータ:Sham Control
Renal Angiogram |
Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Average Daytime Ambulatory Systolic BP
時間枠:From baseline to 2 months post-procedure
|
The primary efficacy outcome is the mean change in daytime ambulatory systolic blood pressure at 2 months |
From baseline to 2 months post-procedure
|
|
Percentage of Participants With Major Adverse Events (MAE)
時間枠:From baseline to 30 days post-procedure
|
The primary safety composite outcome of major adverse events included death, kidney failure, and major embolic, vascular, cardiovascular, cerebrovascular, and hypertensive events at 30 days. |
From baseline to 30 days post-procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Average 24-hr Ambulatory Systolic BP
時間枠:From baseline to 2 months post-procedure
|
Change in average 24-hr ambulatory systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Office Systolic BP
時間枠:From baseline to 2 months post-procedure
|
Change in average office systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Home Systolic BP
時間枠:From baseline to 2 months post-procedure
|
Change in average home systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Daytime Ambulatory Diastolic BP
時間枠:From baseline to 2 months post-procedure
|
Change in average daytime ambulatory diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average 24-hr Ambulatory Diastolic BP
時間枠:From baseline to 2 months post-procedure
|
Change in average 24-hr ambulatory diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Office Diastolic BP
時間枠:From baseline to 2 months post-procedure
|
Change in average office diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Home Diastolic BP
時間枠:From baseline to 2 months post-procedure
|
Change in average home diastolic blood pressure |
From baseline to 2 months post-procedure
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ajay Kirtane, MD, SM、Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation
- 主任研究者:Prof. Michel Azizi, MD, PhD、Professor of Vascular Medicine, Hypertension Dept. and Clinical Investigation Center, Hôpital Européen Georges Pompidou
出版物と役立つリンク
一般刊行物
- Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder RE, Mahfoud F, Lindsey J, Sanghvi K, Todoran TM, Pacella J, Flack J, Daemen J, Sharp ASP, Lurz P, Bloch MJ, Weber MA, Lobo MD, Basile J, Claude L, Reeve-Stoffer H, McClure CK, Kirtane AJ; RADIANCE II Investigators and Collaborators. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023 Feb 28;329(8):651-661. doi: 10.1001/jama.2023.0713.
- Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F, Schmieder RE, Basile J, Bloch MJ, Saxena M, Wang Y, Sanghvi K, Jenkins JS, Devireddy C, Rader F, Gosse P, Claude L, Augustin DA, McClure CK, Kirtane AJ; RADIANCE Investigators. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. Circulation. 2024 Mar 5;149(10):747-759. doi: 10.1161/CIRCULATIONAHA.123.066941. Epub 2023 Oct 26.
- Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, Lobo MD, Lurz P, Basile J, Bloch MJ, Weber MA, Saxena M, Wang Y, Sanghvi K, Jenkins JS, Devireddy C, Rader F, Gosse P, Sapoval M, Barman NC, Claude L, Augustin D, Thackeray L, Mullin CM, Azizi M; RADIANCE Investigators and Collaborators. Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. JAMA Cardiol. 2023 May 1;8(5):464-473. doi: 10.1001/jamacardio.2023.0338.
- Bytyqi V, Kannenkeril D, Striepe K, Bosch A, Karg MV, Schmid A, Schiffer M, Uder M, Schmieder RE. Predicting blood pressure response to renal denervation based on a new approach. J Hypertens. 2025 Mar 1;43(3):413-419. doi: 10.1097/HJH.0000000000003918. Epub 2024 Oct 29.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。